ライフサイエンスコーパス: falciparum

1 ei rhodesiense and falcipain-2 of Plasmodium falciparum.

2 irst genome-wide nascent RNA profiling in P. falciparum.

3 activity against liver and blood stages of P falciparum.

4 cking vaccine (TBV) candidate for Plasmodium falciparum.

5 lication throughout schizogony in Plasmodium falciparum.

6 rs of the human malaria parasite, Plasmodium falciparum.

7 difference in the Fulani susceptibility to P.falciparum.

8 ys with proteasomes isolated from Plasmodium falciparum.

9 lled Human Malaria Infection with Plasmodium falciparum.

10 virulent human malaria parasite, Plasmodium falciparum.

11 of malaria in humans is caused by Plasmodium falciparum.

12 he human malaria-causing parasite Plasmodium falciparum.

13 ation, affecting most laboratory lines of P. falciparum.

14 r severe malaria in adults diagnosed with P. falciparum.

15 nt role in asexual development of Plasmodium falciparum.

16 s a potential target for vaccines against P. falciparum.

17 R0 and R2), and AMA1 antigens of Plasmodium falciparum.

18 quito bite: a major challenge for Plasmodium falciparum.

19 nt were Plasmodium vivax (14.3%), Plasmodium falciparum (10.5%) and Plasmodium malariae (3.4%).

20 Treatment of Plasmodium falciparum 3D7 parasites with peptide corresponding to t

21 s noteworthy growth inhibitors of Plasmodium falciparum (3D7 and W2) in culture.

22 ctron microscopy structure of the Plasmodium falciparum 80S ribosome with the (+)-mefloquine enantiom

23 lts to the species level revealed Plasmodium falciparum (92.0%), Plasmodium ovale (5.6%), and Plasmod

24 active pericentromeric heterochromatin in P. falciparum, a region devoid of the characteristic H3K9me

25 nancy and birth outcomes owing to Plasmodium falciparum accumulation in the placenta.

26 In contrast to canonical actin, P. falciparum actin 1 (PfAct1) does not readily polymerize

27 esent study antibody responses to Plasmodium falciparum AMA-1, MSP-119 and CSP were measured with the

28 ametocyte prevalence decreased 3-fold for P. falciparum and 29% for P. vivax from 2010 to 2014.

29 ecreased 5-fold from 2006 to 2010; 72% of P. falciparum and 87% of P. vivax infections were submicros

30 y against a multidrug resistant strain of P. falciparum and arrest parasites at the ring phase of the

31 INTERPRETATION: P falciparum and P vivax malaria in pregnancy both increas

32 me motor complex (GAP50, GAPM1-3) of both P. falciparum and P. berghei.

33 tory activity against multiple strains of P. falciparum and P. vivax in vitro, is efficacious against

34 strongly inhibited oocyst development of P. falciparum and Plasmodium berghei expressing PfCelTOS in

35 of five human-infecting species: Plasmodium falciparum and Plasmodium knowlesi.

36 pecies causing malaria in humans, Plasmodium falciparum and Plasmodium vivax, rely on two distinct ho

37 The malaria parasite Plasmodium falciparum and related apicomplexan pathogens contain an

38 hat the unexpected target of actinonin in P. falciparum and Toxoplasma gondii is FtsH1, a homolog of

39 related human parasitic pathogens Plasmodium falciparum and Toxoplasma gondii.

40 ples from Cambodian patients infected with P falciparum and treated with dihydroartemisinin-piperaqui

41 used by the Apicomplexan parasite Plasmodium falciparum, and results in significant global morbidity

42 - and the prevalence of antibodies to two P. falciparum antigens (MSP-1, AMA-1).

43 ning chimeric rodent parasites expressing P. falciparum antigens and a flow cytometric readout of inf

44 Antibodies specific for P. falciparum antigens were determined in uncomplicated hyp

45 ch may influence the emergence of Plasmodium falciparum artemisinin-resistant phenotypes and genotype

46 re identified: (1) children infected with P. falciparum as detected by rapid diagnostic testing (RDT)

47 ays for a total of six doses) to eliminate P falciparum before the first and last vaccinations.

48 0 pM in a PfPKG kinase assay and inhibits P. falciparum blood stage proliferation in vitro with an EC

49 itical for asexual development of Plasmodium falciparum, but its precise function and substrates rema

50 sinin-resistant and -sensitive strains of P. falciparum by combining liquid chromatography-mass spect

51 t least one P. vivax parasitaemia and 10% P. falciparum, by qPCR, both of which were predominantly su

52 st that the dominant artemisinin-resistant P falciparum C580Y lineage probably arose in western Cambo

53 suggest that protective immunity against P. falciparum can be achieved via multiple mechanisms and h

54 er various environmental perturbations in P. falciparum can yield quantitative insights into fundamen

55 exposure to the malaria parasite Plasmodium falciparum cause an accumulation of specific responses a

56 Plasmodium falciparum causes a spectrum of malarial disease from as

57 Plasmodium falciparum causes malaria in humans with over 450,000 de

58 Plasmodium falciparum causes most life-threatening cases of malaria

59 se promoting factor of the unconventional P. falciparum cell cycle.

60 lysophosphatidylcholine (LysoPC) controls P. falciparum cell fate by repressing parasite sexual diffe

61 Mice immunized with recombinant P. falciparum CelTOS in combination with the glucopyranosyl

62 vel mutation within the gene encoding the P. falciparum chloroquine resistance transporter, PfCRT.

63 didate of malaria is based on the Plasmodium falciparum circumsporozoite protein (CSP), a major surfa

64 reported to be safe and protective against P falciparum controlled human malaria infection in malaria

65 ers of malaria incidence for P. vivax and P. falciparum corresponded to the pre- and first two years

66 xplore antibody binding in the context of P. falciparum CSP, we used negative-stain electron microsco

67 against one of the lead malaria antigens P. falciparum CSP.

68 dazopyridine series targeting the Plasmodium falciparum cyclic GMP-dependent protein kinase (PfPKG).

69 Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is

70 Immunity to P. falciparum declined prior to 2004, preceding the emergen

71 The human malaria parasite, Plasmodium falciparum, depends on a coordinated regulation of gene

72 2-2.30]; I(2)=26.1%; 34 estimates), as did P falciparum detected in placental samples (OR 1.95 [1.48-

73 We assessed Plasmodium falciparum drug resistance markers in parasites collecte

74 Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) media

75 P. falciparum erythrocytic stage growth in vitro is reduced

76 y against asexual blood stages of Plasmodium falciparum, excellent parasite selectivity, and nanomola

77 P. falciparum exclusively infects human erythrocytes during

78 This unexpected response of human mDCs to P. falciparum exhibited a transcriptional program distinct

79 fected controls, women with early Plasmodium falciparum exposure had retarded intrauterine growth bet

80 term decline in the prevalence of Plasmodium falciparum from 40% prevalence in the period 1900-1929 t

81 oth P. berghei and clinically circulating P. falciparum from malaria endemic areas in Kenya, but not

82 We introduce Plasmodium falciparum gametocyte exported protein-5 (PfGEXP5) trans

83 Even submicroscopic levels of Plasmodium falciparum gametocytes can infect mosquitoes and promote

84 ially, also blocks transmission of mature P. falciparum gametocytes to Anopheles stephensi mosquitoes

85 To address this challenge, a Plasmodium falciparum gamma-irradiated long-lived merozoite (LLM) l

86 haracterize the regulatory regions of the P. falciparum gene PF3D7_1234700, encoding a CPW-WPC protei

87 The P. falciparum genome encodes 10 aspartic proteases called p

88 reasons that remain unknown, the Plasmodium falciparum genome has an exceptionally high AT content c

89 ingle nucleotide polymorphisms within the P. falciparum genome were identified and only marginal diff

90 Analysis of multiple Plasmodium falciparum genomes showed that ICAM-1-binding PfEMP1s al

91 this article, we demonstrate that Plasmodium falciparum genomic DNA delivered to the cytosol of human

92 Plasmodium gallinaceum (>80%) and Plasmodium falciparum (>40%) models, an activity that was equivalen

93 Our results suggest that P. falciparum has acquired multiple RIFINs to evade the hos

94 he plasmepsin II/III genes within Plasmodium falciparum has been associated with decreased sensitivit

95 invasion by the malaria parasite Plasmodium falciparum has been possible.

96 Proteases of the malaria parasite Plasmodium falciparum have long been investigated as drug targets.

97 but a higher proportion were positive for P. falciparum histidine rich protein 2 (192/246 [78.0%]) vs

98 t, this sensor was used to detect Plasmodium falciparum histidine-rich protein 2 (PfHRP2), an importa

99 Rapid diagnostic tests based on Plasmodium falciparum histidine-rich protein II (PfHRP-II) and P. f

100 ral flow malaria RDT that targets Plasmodium falciparum histidine-rich protein-II (HRPII) and Plasmod

101 Among potential new biomarkers, a P. falciparum homolog of insulin-degrading enzyme (PfIDEh)

102 Deletions of the Plasmodium falciparum hrp2 (pfhrp2) gene cause false-negative RDT r

103 Deletions of the Plasmodium falciparum hrp2 and hrp3 genes can affect the performanc

104 P. vivax in vitro, is efficacious against P. falciparum in in vivo rodent models, produces parasite r

105 nt strains inhibit development of Plasmodium falciparum in mosquitoes.

106 at occur during sporogonic development of P. falciparum in the mosquito host.

107 e findings in the Xenopus model extend to P. falciparum in vivo, our data suggest that PfCRT might pl

108 lassical LPS response, pointing to unique P. falciparum-induced activation pathways that may explain

109 Our results suggest that the P. falciparum- infected human erythrocyte contains numerous

110 immune effector mechanism against Plasmodium falciparum-infected erythrocytes (IE); however, current

111 y cytokine secretion, mDCs incubated with P. falciparum-infected erythrocytes activated antigen-speci

112 tigen expressed on the surface of Plasmodium falciparum-infected erythrocytes.

113 BRD3914 was evaluated in P. falciparum-infected mice, providing a cure after four or

114 In P. falciparum-infected patients, Vgamma9Vdelta2 T cells pre

115 ement and stage determination for Plasmodium falciparum-infected red blood cells (Pf-iRBCs).

116 th a fever within the previous 14 days and P falciparum infection assessed by RDT who received an ACT

117 asymptomatic individuals with or without P. falciparum infection at the end of the 6-month dry seaso

118 oratory efficacy endpoint of time to first P falciparum infection beginning 28 days after the fifth v

119 Pregnancy-associated Plasmodium falciparum infection impacts the health of mothers and n

120 are fast-acting compounds that can cure a P. falciparum infection in a humanized NOD/SCID mouse model

121 rs significant protection against Plasmodium falciparum infection in humans.

122 identified to be associated with Plasmodium falciparum infection in natural Anopheles gambiae popula

123 istent to more susceptible An. gambiae to P. falciparum infection in the field.

124 dren younger than 5 years with a fever and P falciparum infection increased across sub-Saharan Africa

125 Chronic asymptomatic P. falciparum infection predicted decreased clinical malari

126 dren younger than 5 years with a fever and P falciparum infection received an ACT.

127 icant protection in African adults against P falciparum infection throughout an entire malaria season

128 Anti-FBG serum also reduced >81% of P. falciparum infection to A. gambiae Finally, we showed th

129 Plasmodium falciparum infection was assessed by blood smear microsc

130 during the early immune response against P. falciparum infection, we investigated whether they could

131 red with women with no detected antenatal P. falciparum infection, women with positive RDT findings d

132 27 (66%) from the vaccine group developed P falciparum infection.

133 vaccinees who were protected from Plasmodium falciparum infection.

134 HCM) is a serious complication of Plasmodium falciparum infection.

135 ets the pre-erythrocytic stage of Plasmodium falciparum infection.

136 ignificantly differentially expressed upon P.falciparum infection.

137 eneous effects on the clinical outcome of P. falciparum infection.

138 (CM) is a severe complication of Plasmodium falciparum infection.

139 gens are widely deployed for detection of P. falciparum infection; however, these tests often miss ca

140 s that support liver stage human malaria (P. falciparum) infection in vitro, and also after implantat

141 vo IC50 64 nM), and murine P. berghei and P. falciparum infections (day 4 ED90 0.34 and 0.57 mg kg(-1

142 Chronic asymptomatic Plasmodium falciparum infections are common in endemic areas and ar

143 e studied spatial distribution of Plasmodium falciparum infections to compare simulated effects of th

144 (2) RDT-negative children whose untreated P. falciparum infections were detected retrospectively by P

145 Subpatent antenatal P. falciparum infections were not associated with adverse d

146 e the first line of treatment for Plasmodium falciparum infections worldwide, but artemisinin resista

147 anism proposed for maintenance of chronic P. falciparum infections(7-9).

148 During Plasmodium falciparum infections, erythrocyte-stage parasites inhib

149 en who did or did not harbor asymptomatic P. falciparum infections.

150 low-dose primaquine (PQ) reduces Plasmodium falciparum infectivity before it impacts gametocyte dens

151 he most virulent form of malaria, Plasmodium falciparum, invade erythrocytes.

152 For the malaria parasite Plasmodium falciparum, invasion of host red blood cells (RBCs) is e

153 d with the human malaria parasite Plasmodium falciparum (iRBCs) adhere to the vascular endothelium th

154 Pfhrp2-deleted P. falciparum is a common cause of RDT-/PCR+ malaria among

155 In conclusion, high AT content in P. falciparum is driven by a systematic mutational bias and

156 ity of pepstatin against cultured Plasmodium falciparum is highly variable depending on the commercia

157 Gene expression in Plasmodium falciparum is tightly regulated to ensure successful pro

158 ever, the human malaria parasite, Plasmodium falciparum, is incapable of pyrimidine salvage for mRNA

159 ssociated with drug resistance in Plasmodium falciparum isolated from subjects receiving DP or SP.

160 did a genome-wide association study of 297 P falciparum isolates from Cambodia to investigate the rel

161 rospectively sequenced the genomes of 194 P. falciparum isolates from five sites in Northwest Thailan

162 is observational study, we tested Plasmodium falciparum isolates from Myanmar, northeastern Thailand,

163 re performed by sequential cloning of six P. falciparum isolates growing in human erythrocytes in vit

164 on in malaria parasites, clinical Plasmodium falciparum isolates were sampled from patients and cultu

165 the benzoxaborole AN3661 against Plasmodium falciparum laboratory-adapted strains (mean IC50 32 nM),

166 Reports of P. falciparum lacking this protein are increasing, creating

167 histidine-rich protein II (PfHRP-II) and P. falciparum lactate dehydrogenase (PfLDH) antigens are wi

168 icans to fatal pathogens, such as Plasmodium falciparum, Lassa Virus and Trypanosoma brucei rhodesien

169 generation of transgenic DiCre-expressing P. falciparum lines in any genetic background.

170 Multiple P. falciparum lines selected in vitro for resistance to AN3

171 individuals or from in vitro cultures of P. falciparum, making them prone to high variation.

172 P falciparum malaria detected and treated during pregnancy

173 Plasmodium falciparum malaria detected at delivery in peripheral sa

174 as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidr

175 We report a case of severe falciparum malaria following nosocomial Plasmodium falci

176 Elimination of falciparum malaria from this region should be accelerate

177 ations that confer artemisinin resistance in falciparum malaria have multiple independent origins acr

178 arative analysis of treatment regimen for P. falciparum malaria in adults in Stockholm during 2000-20

179 laria test (UMT) for diagnosis of Plasmodium falciparum malaria in febrile patients.

180 reasing, creating a problem for diagnosis of falciparum malaria in locations without quality-assured

181 to AL for the treatment of uncomplicated P. falciparum malaria in pediatric patients.

182 The association between P falciparum malaria in pregnancy and stillbirth was two t

183 demic sub-Saharan Africa are attributed to P falciparum malaria in pregnancy; the population attribut

184 Although the burden of Plasmodium falciparum malaria is gradually declining in many parts

185 administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some setting

186 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximately 1 muM).

187 a-regression analysis of cure rates from all falciparum malaria treatment trials (n = 40) with monoth

188 Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 art

189 pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substan

190 ended treatment for uncomplicated Plasmodium falciparum malaria worldwide.

191 ria, severe (n = 21) and nonsevere (n = 109) falciparum malaria, and healthy controls (n = 50), we me

192 In falciparum malaria, angiopoietin-2 increased with age, i

193 relatively better protection from Plasmodium falciparum malaria, as reflected by fewer symptomatic ca

194 urrent treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spreading acro

195 eved to confer protection against Plasmodium falciparum malaria, but the precise nature of the protec

196 ia correlates with the development of severe falciparum malaria, suggesting that platelets either con

197 acious treatment of uncomplicated Plasmodium falciparum malaria.

198 fectively treating drug-resistant Plasmodium falciparum malaria.

199 ts aged 6 months to 12 years with Plasmodium falciparum malaria.

200 besity, is associated with severe Plasmodium falciparum malaria.

201 nsidered for rescue treatment for Plasmodium falciparum malaria.

202 sults of PCR for the detection of Plasmodium falciparum malaria.

203 opoietin-2, and microvascular dysfunction in falciparum malaria.

204 oscopy or rapid test confirmed uncomplicated falciparum malaria.

205 ren from severe and uncomplicated Plasmodium falciparum malaria.

206 ms that confer the lower susceptibility to P.falciparum malaria.

207 n on maintenance of antibodies to Plasmodium falciparum merozoite antigens and infected erythrocytes

208 Invasion of erythrocytes by Plasmodium falciparum merozoites is necessary for malaria pathogene

209 P. falciparum merozoites that lack PfMSP3.1 showed a marked

210 In this article, we show that Plasmodium falciparum merozoites, the invasive form of blood stage

211 have slowed the development of a Plasmodium falciparum multiantigen vaccine.

212 Spread of pfhrp2-deleted P. falciparum mutants, resistant to detection by HRP2-based

213 cking robust adaptive immunity to Plasmodium falciparum Nevertheless, the host may partly control blo

214 he mitochondria of Plasmodium falciparum (P. falciparum) NF54-attB blood-stage parasites and evaluate

215 a deadly outcome of infection by Plasmodium falciparum, occurring when parasite-infected erythrocyte

216 e cytosol and the mitochondria of Plasmodium falciparum (P. falciparum) NF54-attB blood-stage parasit

217 ce and spread of fit artemisinin-resistant P falciparum parasite lineages, which then acquire partner

218 approach to detect hotspots using Plasmodium falciparum parasite prevalence and serological evidence

219 cations of human infection by the Plasmodium falciparum parasite.

220 Plasmodium falciparum parasitemia was less frequent than in non-BWF

221 gametocytes and asynchronous blood-stage P. falciparum parasites by microarray technology.

222 sess potent antimalarial activity against P. falciparum parasites comparable to the known antimalaria

223 hallenged with double chimeric P. berghei-P. falciparum parasites expressing both PfUIS3 and PfTRAP,

224 e recalled in human volunteers exposed to P. falciparum parasites in a controlled human malaria infec

225 PfHRP2-only RDTs is sufficient to select P. falciparum parasites lacking this protein, thus posing a

226 of Mali) for eligibility (>/=2000 asexual P falciparum parasites per muL of blood).

227 g whether successful sporogony of Plasmodium falciparum parasites through to human-infectious transmi

228 Therefore, binding of P. falciparum parasites to the erythrocyte directly activat

229 usly enriches pLDH and HRPII from Plasmodium falciparum parasitized blood samples.

230 ne knockouts were not viable in the human P. falciparum pathogen, we used conditional knockdowns to d

231 observational cohort study, we evaluated P. falciparum pathogenesis in vitro in RBCs from pregnant w

232 The best ligands inhibited Plasmodium falciparum (Pf) and Arabidopsis thaliana (At) SHMT in ta

233 s, children acquired equal numbers of new P. falciparum (Pf) and Pv blood-stage infections/year (Pf-m

234 phoribosyltransferase (HGPRT) and Plasmodium falciparum (Pf) hypoxanthine-guanine-xanthine phosphorib

235 man malaria infection (CHMI) with Plasmodium falciparum (Pf) parasites homologous to the vaccine stra

236 ization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (PfSPZ) inoculated by mosqui

237 SP), the major surface antigen of Plasmodium falciparum (Pf) sporozoites, can protect from malaria in

238 ter of the human malaria parasite Plasmodium falciparum, PfCRT, is an important determinant of resist

239 The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria tr

240 P. falciparum phenotypic plasticity is linked to the varian

241 Bicyclic azetidines targeting Plasmodium falciparum phenylalanyl-tRNA synthetase comprise one pro

242 pyridine that selectively targets Plasmodium falciparum PKG, inhibits blood stage parasite growth in

243 P. falciparum population genetic approaches offer promising

244 esistance in the malaria parasite Plasmodium falciparum poses a major threat to the control and elimi

245 A total 1392 P. falciparum positive samples collected from eight endemic

246 to serve a different function in Plasmodium falciparum, protecting ookinetes from the mosquito immun

247 Placental accumulation is mediated by P. falciparum protein VAR2CSA, a leading PAM-specific vacci

248 eened proteomic data for highly expressed P. falciparum proteins and compared their features to those

249 asmodium yoelii orthologs of four Plasmodium falciparum proteins identified by an antibody-based geno

250 falciparum proteins prepared using the wheat germ cell-f

251 have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to inve

252 th the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF an

253 ibrate close to the level seen across the P. falciparum reference genome (80.6% AT).

254 The emergence of Plasmodium falciparum resistant to frontline therapeutics has promp

255 he Erythrocyte binding antigen family and P. falciparum reticulocyte binding-like families.

256 For instance, Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5

257 Plasmodium falciparum reticulocyte-binding protein homologue 2b (Pf

258 parasitaemia undetectable in vivo using a P. falciparum SCID mouse model.

259 humans and appears to be protective against falciparum severe malaria.

260 any genes of the malaria parasite Plasmodium falciparum show clonally variant expression regulated at

261 Plasmodium falciparum-specific antibody kinetics during the dry sea

262 The performance of Plasmodium falciparum-specific histidine-rich protein 2-based rapid

263 Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically

264 nsgenic P. berghei parasites that express P. falciparum sporozoite antigens, we have been able to use

265 t the prevalence and intensity of Plasmodium falciparum sporozoite infection is significantly lower i

266 live-attenuated malaria vaccine, Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), confers s

267 ) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Ro

268 t CHMI with a low or high dose of Plasmodium falciparum sporozoites.

269 ndemic areas in Kenya, but not laboratory P. falciparum strain NF54.

270 ests can give false-negative results when P. falciparum strains do not express this antigen.

271 Alarmingly, P. falciparum strains have acquired resistance to ART acros

272 itive (NF54) and -resistant (Dd2 and 7G8) P. falciparum strains with 5/6 having IC50 < 100 nM against

273 d stages of drug-sensitive and -resistant P. falciparum strains, inhibits development of P. berghei i

274 The earliest transcriptomics studies in P. falciparum suggested a cascade of transcriptional activi

275 genome-wide association study of ex vivo P. falciparum susceptibility to piperaquine.

276 ent or replication of blood-stage Plasmodium falciparum The percentage of Plasmodium-infected (iRBCs)

277 und that the activation of DCs by Plasmodium falciparum, the main causative agent of human malaria, i

278 For Plasmodium falciparum, the most widespread and virulent malaria par

279 For Plasmodium falciparum, the species responsible for the most severe

280 tro activity against different strains of P. falciparum, the toxicity, and the metabolic stability is

281 in malaria effector proteins from Plasmodium falciparum These findings imply a role for the RxLR moti

282 coadministered with the vaccine candidate P. falciparum thrombospondin-related adhesion protein (PfTR

283 ave characterised replication dynamics in P. falciparum throughout schizogony, using DNA fibre labell

284 In this study, we report that the P. falciparum translation enhancing factor (PTEF) relieves

285 established mathematical model of Plasmodium falciparum transmission dynamics with epidemiological, i

286 thogen recognition molecule in inhibiting P. falciparum transmission in malaria endemic areas.

287 arum malaria following nosocomial Plasmodium falciparum transmission in nonendemic Germany.

288 efforts to model the changing patterns of P. falciparum transmission intensity in Africa have been li

289 gent-based stochastic simulation model of P. falciparum transmission was used to investigate the sele

290 ested at each antenatal visit for Plasmodium falciparum, using an RDT and polymerase chain reaction a

291 enotypes and Abs specific for the Plasmodium falciparum vaccine candidate apical membrane Ag-1 (AMA1)

292 P. falciparum virulence is related to adhesion and sequestr

293 ted mice and the 48-hour in vitro cycle of P falciparum was <10%.

294 Antibody response to P. falciparum was determined in 4,112 individuals by ELISA

295 malaria treatment until resistant Plasmodium falciparum was identified.

296 r in the human malarial parasite, Plasmodium falciparum, we have quantified cytosolic labile heme lev

297 tage-specific molecular methods to detect P. falciparum, we show that gametocytes-and not their nonin

298 The study suggests that early exposure to P. falciparum, which is not targeted for prevention by curr

299 ction with the protozoan parasite Plasmodium falciparum, which requires immediate treatment.

300 (PA) is critical for survival of Plasmodium falciparum within human erythrocytes.